NeoGenomics Stock (NASDAQ:NEO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$14.12

52W Range

$11.79 - $21.22

50D Avg

$15.95

200D Avg

$15.24

Market Cap

$1.79B

Avg Vol (3M)

$758.86K

Beta

1.18

Div Yield

-

NEO Company Profile


NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

US

Employees

2,100

IPO Date

Mar 16, 2004

Website

NEO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Clinical Services$495.64M$418.75M$404.17M
Pharma Services-$90.97M$80.16M

Fiscal year ends in Dec 23 | Currency in USD

NEO Financial Summary


Dec 23Dec 22Dec 21
Revenue$591.64M$509.73M$484.33M
Operating Income$-107.74M$-153.11M$-9.99M
Net Income$-87.97M$-144.25M$-8.35M
EBITDA$-6.52M$-83.89M$43.36M
Basic EPS$-0.70$-1.16$-0.07
Diluted EPS$-0.70$-1.16$-0.07

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Jul 29, 24 | 8:14 PM
Q1 24Apr 30, 24 | 12:00 AM
Q4 23Feb 20, 24 | 7:20 PM

Peer Comparison


TickerCompany
GHGuardant Health, Inc.
IQVIQVIA Holdings Inc.
CDNACareDx, Inc
NTRANatera, Inc.
ICLRICON Public Limited Company
TWSTTwist Bioscience Corporation
QGENQiagen N.V.
CSTLCastle Biosciences, Inc.
ACRSAclaris Therapeutics, Inc.
NEOGNeogen Corporation
OLKOlink Holding AB (publ)
CRLCharles River Laboratories International, Inc.
MTDMettler-Toledo International Inc.
BDSXBiodesix, Inc.
MYGNMyriad Genetics, Inc.
SHCSotera Health Company